How does chemotherapy disrupt circadian rhythms?

Updated on: October 04,2025 0

How does chemotherapy disrupt circadian rhythms?

Updated on:October 04,2025 0

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Updated on: October 04,2025 0

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Updated on:October 04,2025 0

Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows

Updated on: October 04,2025 0

Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows

Updated on:October 04,2025 0

How brain fluid dynamics drive cancer spread—and ways to fight back

Updated on: October 03,2025 0

How brain fluid dynamics drive cancer spread—and ways to fight back

Updated on:October 03,2025 0

Video-assisted thoracoscopy surgery reduces mortality by 21% compared to lobectomy, meta-analysis suggests

Updated on: October 03,2025 0

Video-assisted thoracoscopy surgery reduces mortality by 21% compared to lobectomy, meta-analysis suggests

Updated on:October 03,2025 0

Simultaneous cell isolation technology shows clinical feasibility for increased accuracy in cancer diagnostics

Updated on: October 03,2025 0

Simultaneous cell isolation technology shows clinical feasibility for increased accuracy in cancer diagnostics

Updated on:October 03,2025 0

Antioxidant shield for T cell telomeres shows promise against tumor-induced exhaustion

Updated on: October 03,2025 0

Antioxidant shield for T cell telomeres shows promise against tumor-induced exhaustion

Updated on:October 03,2025 0

Study highlights communication gaps and need for shared decision-making in lung cancer diagnosis

Updated on: October 03,2025 0

Study highlights communication gaps and need for shared decision-making in lung cancer diagnosis

Updated on:October 03,2025 0

Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

Updated on: October 03,2025 0

Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

Updated on:October 03,2025 0

Clinical study deepens understanding of mesothelioma, opens the door to potential treatment options

Updated on: October 03,2025 0

Clinical study deepens understanding of mesothelioma, opens the door to potential treatment options

Updated on:October 03,2025 0